等待開盤 01-28 09:30:00 美东时间
+0.010
+0.51%
Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Dec. 11, 2025 /PRNewswire/ -- Equity Insider News Commentary – November's wave of FDA oncology approvals signals the industry's shift to...
2025-12-11 23:17
OmniAb, Inc. (NASDAQ:OABI) and ArrowMark Partners ("ArrowMark") today announced the signing of a license and services agreement for novel OmniAb-derived antibody discovery programs with Mabtrx Biosciences, a wholly owned
2025-11-18 06:28
The most oversold stocks in the health care sector presents an opportunity to b...
2025-08-26 19:12
OmniAb (NASDAQ:OABI) has entered into a definitive agreement for a private placement of its common stock to raise approximately $30 million in gross proceeds. The company will issue and sell a total o...
2025-08-25 19:34
An update from OmniAb ( ($OABI) ) is now available. On August 24, 2025, OmniAb,...
2025-08-25 19:28
RBC Capital analyst Conor McNamara maintains OmniAb (NASDAQ:OABI) with a Outperform and lowers the price target from $4 to $3.
2025-08-07 23:11
OmniAb (NASDAQ:OABI) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.16) by 4.46 percent. This is a 15.38 percent decrease over losses of $(0.13) per share from the same
2025-08-07 06:51
OmniAb (NASDAQ:OABI) affirms FY2025 sales outlook from $20.000 million-$25.000 million to $20.000 million-$25.000 million vs $22.970 million estimate.
2025-08-07 05:54
Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, June 30, 2025 /PRNewswire/ -- Several experts are seeing that value of AI's total overhaul of health...
2025-06-30 21:50